Press coverage about DBV Technologies (NASDAQ:DBVT) has trended somewhat negative this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DBV Technologies earned a daily sentiment score of -0.15 on Accern’s scale. Accern also assigned media stories about the company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- DBV Technologies S.A. – America (DBVT) Saw a 52-Week High (highlightpress.com)
- DBV Technologies Initiates Phase III Study of V… (trustnet.com)
- DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age (finance.yahoo.com)
Shares of DBV Technologies (DBVT) traded down 3.34% on Tuesday, reaching $44.63. The company’s stock had a trading volume of 75,507 shares. The stock has a 50-day moving average of $39.56 and a 200 day moving average of $35.79. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $45.98. The stock’s market capitalization is $2.05 billion.
Several research analysts recently issued reports on the company. BidaskClub upgraded DBV Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research upgraded DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 price objective for the company in a research report on Tuesday, August 1st. ValuEngine upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Jefferies Group LLC restated a “buy” rating and set a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a research report on Thursday, July 6th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. DBV Technologies has an average rating of “Buy” and a consensus price target of $48.83.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with our FREE daily email newsletter.